<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>p16 and p15, 2 inhibitors of cyclin-dependent kinases, are frequently hypermethylated in hematologic <z:hpo ids='HP_0002664'>neoplasias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi>, or <z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi>, reverts hypermethylation of these genes in vitro, and low-dose <z:chebi fb="0" ids="50131">decitabine</z:chebi> treatment improves cytopenias and blast excess in ~50% of patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We examined p15 and p16 methylation status in bone marrow mononuclear cells from patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> during treatment with <z:chebi fb="0" ids="50131">decitabine</z:chebi>, using a methylation-sensitive primer extension assay (Ms-SNuPE) to quantitate methylation, and denaturing gradient gel electrophoresis (DGGE) and <z:chebi fb="0" ids="17137">bisulfite</z:chebi>-DNA sequencing to distinguish individually methylated alleles </plain></SENT>
<SENT sid="3" pm="."><plain>p15 expression was serially examined in bone marrow biopsies by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>Hypermethylation in the 5' p15 gene region was detected in 15 of 23 patients (65%), whereas the 5' p16 region was unmethylated in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Among 12 patients with hypermethylation sequentially analyzed after at least one course of <z:chebi fb="0" ids="50131">decitabine</z:chebi> treatment, a decrease in p15 methylation occurred in 9 and was associated with clinical response </plain></SENT>
<SENT sid="6" pm="."><plain>DGGE and sequence analyses were indicative of hypomethylation induction at individual alleles </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemical staining for p15 protein in bone marrow biopsies from 8 patients with p15 hypermethylation revealed low or absent expression in 4 patients, which was induced to <z:mpath ids='MPATH_458'>normal</z:mpath> levels during <z:chebi fb="0" ids="50131">decitabine</z:chebi> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, frequent, selective p15 hypermethylation was reversed in responding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients following treatment with a methylation inhibitor </plain></SENT>
<SENT sid="9" pm="."><plain>The emergence of partially demethylated epigenotypes and re-establishment of <z:mpath ids='MPATH_458'>normal</z:mpath> p15 protein expression following the initial <z:chebi fb="0" ids="50131">decitabine</z:chebi> courses implicate pharmacologic demethylation as a possible mechanism resulting in hematologic response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>